Science of premix insulin: where have we reached?

References

• Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Esposito K, Chiodini P, Bellastella G, et al. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012;14:228-33
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-15
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Mark M, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
   PubMed Web of Science ®Google Scholar
• Cucinotta D, Russo GT. Biphasic insulin aspart in the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2009;10:2905-11
   PubMed Web of Science ®Google Scholar
• Peyrot M, Barnett AH, Meneghini LF, et al. Factors associated with injection omission/non-adherence in the Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetes Obes Metab 2012;10.1111/j.1463-1326.2012.01636.x. [Epub ahead of print]
   PubMedGoogle Scholar
• Goodall G, Sarpong EM, Hayes C, et al. The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycemic agents: a modelling study. BMC Endocr Disord 2009;9:19
   PubMed Web of Science ®Google Scholar
• Mosezon O, Raz I. Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? Diabetes Care 2013;36:S212-18
   Google Scholar
• Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5
   PubMed Web of Science ®Google Scholar
• Malone JK, Kerr LF, Campaigne BN, et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26:2034-44
   PubMed Web of Science ®Google Scholar
• Malone JK, Bai S, Campaigne BN, et al. Twice daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005;22:374-81
   PubMed Web of Science ®Google Scholar
• Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications 2006;20:145-52
   PubMed Web of Science ®Google Scholar
• Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30
   PubMed Web of Science ®Google Scholar
• Robbins DC, Beisswenger PJ, Ceriello A, et al. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29:2349-64
   PubMed Web of Science ®Google Scholar
• Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32:1007-13
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Mechanick JI, Blonde L, et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011;17:S1-53
   PubMedGoogle Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:S1-S201
   Google Scholar
• International Diabetes Federation. Clinical guidelines task force. Global guideline for type 2 diabetes. Available from: www.idf.org/sites/default/files/IDF%20T2DM%20Guideline.pdf [Last accessed on 22 April 2014]
   Google Scholar
• Guidelines for Management of Type 2 diabetes by the Indian Council of Medical Research. 2005. Available from: www.icmr.nic.in/guidelines_diabetes/guide_diabetes.htm [Last accessed on 2 April 2014]
   Google Scholar
• Dailey GE. Early insulin: an important therapeutic strategy. Diabetes Care 2005;28:220-1
   PubMed Web of Science ®Google Scholar
• Tibaldi JM. Evolution of insulin development: focus on key parameters. Adv Ther 2012;29:590-619
   PubMed Web of Science ®Google Scholar
• Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001;22:706-17
   PubMed Web of Science ®Google Scholar
• Howey DC, Bowsher RR, Brunelle RL, et al. [Lys (B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, et al. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 2011;34:510-17
   PubMed Web of Science ®Google Scholar
• Rotenstein L S, Benjamin M, Kozak et al. Close. The Ideal Diabetes Therapy: what Will It Look Like? How close are we? Clin Diabetes 2012;30:44-53
   Google Scholar
• Fakhoury WK, Richter H, Christensen TE. Real-life dosage and clinical efficacy of biphasic insulin preparations in patients with type 2 diabetes. Adv Ther 2010;27:859-69
   PubMedGoogle Scholar
• Liebl A, Prusty V, Valensi P, et al. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings. Drugs 2012;72:1495-520
   PubMedGoogle Scholar
• Qayyum R, Greene L. AHRQ’s comparative effectiveness research on premixed insulin analogues for adults with type 2 diabetes: understanding and applying the systematic review findings. J Manag Care Pharm 2011;17:S3-19
   Google Scholar
• Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007;18:56-62
   PubMed Web of Science ®Google Scholar
• Ligthelm RJ. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice. Prim Care Diabetes 2009;3:97-102
   PubMedGoogle Scholar
• Oyer DS, Shepherd MD, Coulter FC, et al. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATE plus trial). Am J Med 2009;122:1043-9
   PubMed Web of Science ®Google Scholar
• Hosoi Y, Ohtani K, Shimizu H, et al. Attainment of glycaemic goals by step-up therapy with biphasic insulin aspart-70/30 in Japanese type 2 diabetic patients. Endocr J 2011;58:131-5
   PubMedGoogle Scholar
• Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004;26:531-40
   PubMed Web of Science ®Google Scholar
• Boehm BO, Home PD, Behrend C, et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393-9
   PubMed Web of Science ®Google Scholar
• Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002;25:883-8
   PubMed Web of Science ®Google Scholar
• Luzio S, Dunseath G, Peter R, et al. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia 2006;49:1163-8
   PubMed Web of Science ®Google Scholar
• Boehm BO, Vaz JA, Brøndsted L, et al. Long-term efficacy and safety of biphasic insulin aspart in patients with type 2 diabetes. Eur J Intern Med 2004;15:496-502
   PubMedGoogle Scholar
• Abrahamian H, Ludvik B, Schernthaner G, et al. Improvement of glucose control in Type 2 diabetic patients. Traditional versus modern insulin regimens. Horm Metab Res 2005;37:684-9
   PubMed Web of Science ®Google Scholar
• Iwamato Y. A randomized, multicentric trial of Biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia 2003;46:A270
   Google Scholar
• Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008;149:549-59
   PubMed Web of Science ®Google Scholar
• Davidson JA, Liebl A, Christiansen JS, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis. Clin Ther 2009;31:1641-51
   PubMed Web of Science ®Google Scholar
• Garber AJ, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes Obes Metab 2006;8:58-66
   PubMed Web of Science ®Google Scholar
• Freeman JS. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus. J Am Osteopath Assoc 2012;112:S2-6
   PubMedGoogle Scholar
• Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999;15:205-18
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care 1998;21:42-8
   PubMed Web of Science ®Google Scholar
• Brunton SA, White JRJr, Renda SM. The role of basal insulin in type 2 diabetes management. J Fam Pract 2005;S1-8
   Google Scholar
• Shah S, Zilov A, Malek R, et al. Improvements in quality of life associated with insulin analogue therapies in people with type 2 diabetes: results from the A1chieve observational study. Diabetes Res Clin Pract 2011;94:364-70
   PubMed Web of Science ®Google Scholar
• Niskanen L, Leiter LA, Franek E, et al. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol 2012;167:287-94
   PubMed Web of Science ®Google Scholar
• Fulcher G, Bantwal G, Poplawska E, et al. Insulin degludec/insulin aspart achieves superior FPG and less hypoglycaemia vs. biphasic insulin aspart 30 in poorly controlled T2DM. Presented at International Diabetes Federation (IDF), World Diabetes Congress. Melbourne, Australia, December 2013; Poster #1399
   Google Scholar
• Christiansen JS, Chow F, Seop Choi D, et al. Superior FPG control and less nocturnal hypoglycaemia with IDegAsp vs BIAsp 30 in Asian subjects poorly controlled on basal or pre/self-mixed insulin: randomised phase 3 trial. Diabetologia 2013;56:S420; Abstract 1045
   Google Scholar
• Fulcher G, Vaag A, Christiansen J, et al. Lower rates of hypoglycaemia with insulin degludec/insulin aspart versus biphasic insulin aspart 30 in patients with T2D: a meta-analysis. Presented at the World Diabetes Congress; 2-6 December 2013; Melbourne, Australia
   Google Scholar
• Vaag A, Christiansen JS, Niskanen L, et al. Lower rates of overall, nocturnal and severe hypoglycaemia during maintenance treatment with IDegAsp vs. biphasic insulin aspart 30 in patients with T2D: a meta-analysis. Diabetologia 2013;56:S83; Abstract 187
   Google Scholar
• Vaag AA, Chriastinsen JS, Niskanen L, et al. IDegAsp lowers the Rate of Hypoglycemia vs. Biphasic Insulin Aspart 30 in Adults with T2D Achieving Glycemic Target (HbA1c <7.0%): A Meta-analysis. 888-P ADA 2014
   Google Scholar
• Franek E, Haluzik M, Canecki-varzic S, et al. Insulin Degludec/Insulin Aspart IDegAsp provides Superior FPG Control and Reduced Hypoglycaemia vs. Biphasic Insulin Aspart 30 (BIAsp 30) in insulin-naive adults with Type 2 diabetes in a randomized phase 3 trial. 882-P ADA 2014
   Google Scholar
• Novo Nordisk. Insulin degludec and insulin degludec/insulin aspart treatment to improve glycemic control in patients with diabetes mellitus. Briefing Information for the November 8, 2012 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327017.pdf
   Google Scholar
• U.S. Food and Drug Administration - FDA Briefing Information, Insulin Degludec and Insulin Degludec/Aspart, for the November 8, 2012 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) Assessment Report for Tresiba (insulin degludec). 20 September 2012. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002498/WC500139010.pdf
   Google Scholar